IL156941A0 - Polymer conjugates of neublastin and methods of using same - Google Patents

Polymer conjugates of neublastin and methods of using same

Info

Publication number: IL156941A0
Authority: IL; Israel
Prior art keywords: neublastin; methods; same; polymer conjugates; conjugates
Prior art date: 2001-02-01

Application number

IL15694102A

Other languages

English (en)

Original Assignee

Biogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-01

Filing date

2002-01-25

Publication date

2004-02-08

2002-01-25 Application filed by Biogen Inc filed Critical Biogen Inc

2004-02-08 Publication of IL156941A0 publication Critical patent/IL156941A0/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Zoology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)

IL15694102A 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same IL156941A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26607101P	2001-02-01	2001-02-01
PCT/US2002/002319 WO2002060929A2 (en)	2001-02-01	2002-01-25	Polymer conjugates of neublastin and methods of using same

Publications (1)

Publication Number	Publication Date
IL156941A0 true IL156941A0 (en)	2004-02-08

Family

ID=23013042

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL15694102A IL156941A0 (en)	2001-02-01	2002-01-25	Polymer conjugates of neublastin and methods of using same
IL156941A IL156941A (en)	2001-02-01	2003-07-15	Noblastine polymer couplings and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL156941A IL156941A (en)	2001-02-01	2003-07-15	Noblastine polymer couplings and methods of use

Country Status (35)

Country	Link
EP (2)	EP1862475A1 (uk)
JP (2)	JP4259868B2 (uk)
KR (2)	KR100960063B1 (uk)
CN (1)	CN1500095B (uk)
AR (1)	AR035077A1 (uk)
AT (1)	ATE365748T1 (uk)
AU (1)	AU2002247037B2 (uk)
BG (1)	BG66393B1 (uk)
BR (1)	BR0206852A (uk)
CA (1)	CA2436407C (uk)
CY (1)	CY1106886T1 (uk)
CZ (1)	CZ20032080A3 (uk)
DE (1)	DE60220879T2 (uk)
DK (1)	DK1355936T3 (uk)
EA (1)	EA009771B1 (uk)
EE (1)	EE05537B1 (uk)
ES (1)	ES2289091T3 (uk)
GE (1)	GEP20063916B (uk)
HU (1)	HU228973B1 (uk)
IL (2)	IL156941A0 (uk)
IS (1)	IS2867B (uk)
MX (1)	MXPA03006805A (uk)
MY (1)	MY143685A (uk)
NO (1)	NO332150B1 (uk)
NZ (1)	NZ527863A (uk)
PL (1)	PL211162B1 (uk)
PT (1)	PT1355936E (uk)
RS (1)	RS50857B (uk)
SG (1)	SG149685A1 (uk)
SI (1)	SI1355936T1 (uk)
SK (1)	SK288123B6 (uk)
TR (1)	TR200301208T2 (uk)
UA (2)	UA82983C2 (uk)
WO (1)	WO2002060929A2 (uk)
ZA (1)	ZA200305733B (uk)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7442370B2 (en)	2001-02-01	2008-10-28	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
TR200301208T2 (tr) *	2001-02-01	2005-05-23	Biogen, Inc.	Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.
US7276580B2 (en)	2001-03-12	2007-10-02	Biogen Idec Ma Inc.	Neurotrophic factors
CA2442159C (en) *	2001-03-28	2011-08-23	Biogen, Inc.	Treatment using neublastin polypeptides
PT3025726T (pt) *	2002-01-18	2020-01-09	Biogen Ma Inc	Compostos do polímero polialquileno e utilizações dos mesmos
CA2514510C (en) *	2003-01-31	2013-10-01	Biogen Idec Ma Inc.	Polymer conjugates of mutated neublastin
CA2864810A1 (en)	2003-04-18	2004-11-04	Biogen Idec Ma, Inc.	Polymer-conjugated glycosylated neublastin
US7601518B2 (en) *	2003-06-10	2009-10-13	Nsgene A/S	Secretion of neublastin
US7598059B2 (en)	2003-10-02	2009-10-06	Biogen Idec Ma Inc.	Neublastin expression constructs
GEP20115196B (en) *	2004-08-19	2011-04-11	Biogen Idec Inc	Neublastin variants
ES2349043T3 (es) *	2004-08-19	2010-12-22	Biogen Idec Ma Inc.	Variantes de neublastina.
TWI501774B (zh)	2006-02-27	2015-10-01	Biogen Idec Inc	神經性病症之治療
ES2450065T3 (es) *	2006-03-01	2014-03-21	Biogen Idec Ma Inc.	Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
PL2068935T3 (pl)	2006-09-15	2011-11-30	Creabilis Therapeutics S R L	Polimerowe koniugaty BOX-A HMGB1 i warianty HMGB1
EP2142205B1 (en) *	2007-05-01	2014-04-02	Biogen Idec MA Inc.	Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
CN104023804B (zh) *	2011-11-02	2017-05-24	弗·哈夫曼-拉罗切有限公司	超载和洗脱层析
RU2488635C1 (ru) *	2012-03-22	2013-07-27	Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития	Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6472178B1 (en) *	1998-02-27	2002-10-29	Regeneron Pharmaceuticals, Inc.	Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) *	1994-11-14	1998-06-23	Amgen Inc.	BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) *	1998-07-06	2003-07-15	Nsgene A/S	Neurotrophic factors
JP2002531128A (ja) *	1998-12-09	2002-09-24	アムジエン・インコーポレーテツド	神経栄養因子ｇｒｎｆ４
TR200301208T2 (tr) *	2001-02-01	2005-05-23	Biogen, Inc.	Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.

2002
- 2002-01-25 TR TR2003/01208T patent/TR200301208T2/xx unknown
- 2002-01-25 UA UA2003088104A patent/UA82983C2/uk unknown
- 2002-01-25 UA UAA200802148A patent/UA100967C2/uk unknown
- 2002-01-25 CN CN028077539A patent/CN1500095B/zh not_active Expired - Fee Related
- 2002-01-25 EP EP07110666A patent/EP1862475A1/en not_active Withdrawn
- 2002-01-25 SI SI200230580T patent/SI1355936T1/sl unknown
- 2002-01-25 AU AU2002247037A patent/AU2002247037B2/en not_active Ceased
- 2002-01-25 NZ NZ527863A patent/NZ527863A/en not_active IP Right Cessation
- 2002-01-25 DK DK02714792T patent/DK1355936T3/da active
- 2002-01-25 MX MXPA03006805A patent/MXPA03006805A/es active IP Right Grant
- 2002-01-25 PL PL372101A patent/PL211162B1/pl unknown
- 2002-01-25 KR KR1020087022638A patent/KR100960063B1/ko not_active Expired - Fee Related
- 2002-01-25 CZ CZ20032080A patent/CZ20032080A3/cs unknown
- 2002-01-25 GE GE5240A patent/GEP20063916B/en unknown
- 2002-01-25 SG SG200504719-6A patent/SG149685A1/en unknown
- 2002-01-25 HU HU0500637A patent/HU228973B1/hu not_active IP Right Cessation
- 2002-01-25 IL IL15694102A patent/IL156941A0/xx unknown
- 2002-01-25 PT PT02714792T patent/PT1355936E/pt unknown
- 2002-01-25 CA CA2436407A patent/CA2436407C/en not_active Expired - Fee Related
- 2002-01-25 ES ES02714792T patent/ES2289091T3/es not_active Expired - Lifetime
- 2002-01-25 EE EEP200300355A patent/EE05537B1/xx not_active IP Right Cessation
- 2002-01-25 AT AT02714792T patent/ATE365748T1/de active
- 2002-01-25 KR KR1020037010127A patent/KR100872807B1/ko not_active Expired - Fee Related
- 2002-01-25 AR ARP020100279A patent/AR035077A1/es not_active Application Discontinuation
- 2002-01-25 EP EP02714792A patent/EP1355936B1/en not_active Expired - Lifetime
- 2002-01-25 DE DE60220879T patent/DE60220879T2/de not_active Expired - Lifetime
- 2002-01-25 EA EA200300852A patent/EA009771B1/ru not_active IP Right Cessation
- 2002-01-25 RS YUP-610/03A patent/RS50857B/sr unknown
- 2002-01-25 SK SK971-2003A patent/SK288123B6/sk not_active IP Right Cessation
- 2002-01-25 BR BR0206852-4A patent/BR0206852A/pt not_active Application Discontinuation
- 2002-01-25 JP JP2002561497A patent/JP4259868B2/ja not_active Expired - Fee Related
- 2002-01-25 WO PCT/US2002/002319 patent/WO2002060929A2/en not_active Ceased
- 2002-02-04 MY MYPI20020368A patent/MY143685A/en unknown
2003
- 2003-07-15 IL IL156941A patent/IL156941A/en not_active IP Right Cessation
- 2003-07-17 IS IS6879A patent/IS2867B/is unknown
- 2003-07-24 ZA ZA2003/05733A patent/ZA200305733B/en unknown
- 2003-08-01 NO NO20033441A patent/NO332150B1/no not_active IP Right Cessation
- 2003-08-19 BG BG108111A patent/BG66393B1/bg unknown
2007
- 2007-09-21 CY CY20071101225T patent/CY1106886T1/el unknown
2008
- 2008-10-28 JP JP2008277469A patent/JP4423338B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR100960063B1 (ko)	2010-05-31
GEP20063916B (en)	2006-09-11
CN1500095A (zh)	2004-05-26
IS2867B (is)	2014-02-15
RS50857B (sr)	2010-08-31
HU228973B1 (en)	2013-07-29
CA2436407A1 (en)	2002-08-08
NO332150B1 (no)	2012-07-09
JP4259868B2 (ja)	2009-04-30
HUP0500637A3 (en)	2010-01-28
WO2002060929A3 (en)	2003-03-06
EP1862475A1 (en)	2007-12-05
JP2009039135A (ja)	2009-02-26
CZ20032080A3 (cs)	2003-10-15
SI1355936T1 (sl)	2007-12-31
WO2002060929A2 (en)	2002-08-08
YU61003A (sh)	2006-05-25
AU2002247037B2 (en)	2007-08-16
BG66393B1 (bg)	2013-11-29
CA2436407C (en)	2011-08-30
JP4423338B2 (ja)	2010-03-03
IL156941A (en)	2008-11-03
IS6879A (is)	2003-07-17
UA82983C2 (uk)	2008-06-10
SG149685A1 (en)	2009-02-27
KR20080098662A (ko)	2008-11-11
DK1355936T3 (da)	2007-10-29
BR0206852A (pt)	2005-05-03
EA009771B1 (ru)	2008-04-28
UA100967C2 (uk)	2013-02-25
HUP0500637A2 (hu)	2005-09-28
MY143685A (en)	2011-06-30
SK9712003A3 (en)	2004-01-08
SK288123B6 (sk)	2013-09-03
HK1057759A1 (en)	2004-04-16
BG108111A (bg)	2004-12-30
ZA200305733B (en)	2005-02-23
PT1355936E (pt)	2007-09-28
CN1500095B (zh)	2010-06-16
EP1355936A2 (en)	2003-10-29
NO20033441L (no)	2003-10-01
KR100872807B1 (ko)	2008-12-09
NO20033441D0 (no)	2003-08-01
DE60220879T2 (de)	2008-03-06
TR200301208T2 (tr)	2005-05-23
MXPA03006805A (es)	2003-11-13
EA200300852A1 (ru)	2004-06-24
DE60220879D1 (de)	2007-08-09
PL211162B1 (pl)	2012-04-30
CY1106886T1 (el)	2012-09-26
JP2005503763A (ja)	2005-02-10
KR20030074766A (ko)	2003-09-19
NZ527863A (en)	2006-09-29
ES2289091T3 (es)	2008-02-01
AR035077A1 (es)	2004-04-14
EP1355936B1 (en)	2007-06-27
ATE365748T1 (de)	2007-07-15
PL372101A1 (en)	2005-07-11
EE05537B1 (et)	2012-04-16
EE200300355A (et)	2003-10-15

Publication	Publication Date	Title
AU2002320058A1 (en)	2002-12-16	Magnetic-nanoparticle conjugates and methods of use
PL358335A1 (en)	2004-08-09	Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001285020A1 (en)	2002-02-25	P97-active agent conjugates and their methods of use
GB0116247D0 (en)	2001-08-29	Surgical techniques and devices
IL161255A0 (en)	2004-09-27	Gentle-acting skin-disinfectants and hydroalcoholic gel formulations
AU2002357119A8 (en)	2003-06-30	Mitocidal compositions and methods
GB0111872D0 (en)	2001-07-04	Therapeutic agents and methods
ZA200305733B (en)	2005-02-23	Polymer conjugates of neublastin and methods of using same
IL146842A0 (en)	2002-07-25	Polymer conjugates of hedgehog proteins and uses
GB0121148D0 (en)	2001-10-24	Polymers and their use
AU2002357748A8 (en)	2003-06-10	Osteopontin-related compositions and methods
EP1370240A4 (en)	2004-09-22	NEUROPROTECTOR FORMULATIONS AND METHOD
AU2002359618A1 (en)	2003-06-23	Medicinal compositions and therapeutic methods
HUP0600436A2 (en)	2006-09-28	Catheter composition and uses thereof
EP1421101A4 (en)	2005-01-19	P-GLYCOPROTEINS AND THEIR USES
IL153653A0 (en)	2003-07-06	Novel therapeutic molecular variants and uses thereof
AU2002359869A8 (en)	2003-07-24	Pak5-related compositions and methods
GB0200843D0 (en)	2002-03-06	Benzodioxinopyrroles their preparation and use
AUPR326501A0 (en)	2001-03-15	Guide post and foot member
AU2002345562A1 (en)	2003-01-02	Human tachykinin-related splice variants and compositions thereof
GB0103620D0 (en)	2001-03-28	Sterile composition and its preparation
AUPQ869900A0 (en)	2000-08-03	Novel therapeutic molecular variants and uses thereof - ii
AUPQ998000A0 (en)	2000-10-05	Novel therapeutic molecular variants and uses thereof-iii
AU6569901A (en)	2002-01-08	Novel therapeutic molecular variants and uses thereof
HK1054965A (en)	2003-12-19	Novel therapeutic molecular variants and uses thereof